Jenner & Block's Collins on forces driving pharma M&A - The Deal Pipeline (SAMPLE CONTENT: NEED AN ID?)
Subscriber Content Preview | Request a free trialSearch  
  Go

Video

Share  |  Reprint

Jenner & Block's Collins on forces driving pharma M&A

Published May 9, 2012 at 4:00 AM


The expiration of blockbuster drug patents and the melding of generic and branded drug makers has become one of the driving forces for M&A, according to Jenner & Block LLP's Kevin Collins, who spoke with The Deal Pipeline's David Marcus at Northwestern Law's 32nd Annual Ray Garrett Jr. Corporate and Securities Law Institute. - George White 

Share:

Free preview

This is only a preview of The Deal's sophisticated coverage. Explore the real-time intelligence as researched and reported on by our team of financial journalists with a license to The Deal Pipeline. Click here for more information.

Meet the journalists



Movers & Shakers

Launch Movers and shakers slideshow

Real estate investment manager Clarion Partners LLC hired Kerrisha Jenkins as a vice president in Los Angeles. For other updates launch today's Movers & shakers slideshow.

Video

Goode Partners feasts on IPO returns

The firm's Daniel Bonoff discusses the difficult environment for finding quality targets, but welcomes a hot market for issuers. More video

Sectors